Subtype
Neuroblastic Tumor
CI-CAN-00001274Explore in graph →
137 active trials3 approved drugs28 evidence items
- NCIt
- C6963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001274Explore in graph →
Clinical trials
619 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06851221 | Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma | completed | N/A | 95 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | recruiting | Phase 1 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02030964 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan(DFMO) | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 3 | Feb 17, 2025 | clinicaltrials |
| NCT06000787 | MCT for the Harvard/UCSF ROBIN Center | recruiting | N/A | 47 | Brigham and Women's HospitalOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04903899 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma(LuDO-N) | recruiting | Phase 2 | 24 | Jakob StenmanOTHER | 5 | Feb 11, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | recruiting | Phase 1 | 12 | Nanjing Children's HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | recruiting | Early Phase 1 | 30 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT03649438 | 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | no longer available | — | — | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT00002730 | Chemotherapy in Treating Children With Neuroblastoma | completed | Phase 1 | — | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05826158 | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma | recruiting | N/A | 25 | Rigshospitalet, DenmarkOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT00695279 | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | completed | — | 41 | St. Jude Children's Research HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | terminated | — | 15 | PfizerINDUSTRY | 6 | Sep 23, 2024 | clinicaltrials |
| NCT06438614 | A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma(NICE) | completed | Phase 2 | 47 | Fundació Sant Joan de DéuOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06574698 | Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma | recruiting | — | 64 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT00601003 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | completed | Phase 2 | 112 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | completed | Phase 1 | 21 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01109238 | A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma | completed | — | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01355679 | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma | completed | N/A | 16 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01802567 | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | completed | N/A | 52 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | completed | Phase 2 | 140 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT06502210 | Identification of New Gene Spliceosomes in Neuroblastoma | unknown | — | 20 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT05245123 | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families(PsyRareCare) | completed | — | 100 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03517280 | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil | completed | — | 17 | Columbia UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT02641314 | Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma(METRO-NB2012) | completed | Phase 2 | 18 | University of CologneOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02169609 | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | completed | Phase 2 | 24 | Fundació Sant Joan de DéuOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT02559804 | Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)(NB-SCI) | recruiting | — | 150 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Apr 15, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Feb 28, 2025source: clinicaltrials